The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Marieke E. Straver(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Jelle Wesseling(Leiden University Medical Center), Harm van Tinteren(Netherlands Comprehensive Cancer Organisation), Juliane Hannemann(Universität Hamburg), Annuska M. Glas(Leiden University Medical Center), Marc J. van de Vijver(Amsterdam UMC Location University of Amsterdam), Laura J. van’t Veer(Leiden University Medical Center), Marie-Jeanne T. F. D. Vrancken Peeters(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Emiel J. Rutgers(The Netherlands Cancer Institute)
Cited by 256
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k